With Zero 483 observations
Zydus Cadila's formulations manufacturing facility at Moraiya, Ahmedabad has received an Establishment Inspection Report from the USFDA signifying the successful closure of the audit. The Moraiya manufacturing plant has completed the USFDA audit from 06 February 2017 to 15 February 2017 with Zero 483 observations. Post the audit, the plant has received several product approvals, including the final approval to market Mesalamine Delayed-Release Tablets USP, 1.2 g in the US.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
